SSA
SPRO icon

Schonfeld Strategic Advisors’s Spero Therapeutics SPRO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.5K Buy
+20,314
New +$48.2K ﹤0.01% 1972
2025
Q3 		– Sell
-510,834
Closed -$1.48M – 2552
2025
Q2 		$1.48M Buy
+510,834
New +$735K 0.01% 1134
2018
Q4 		– Sell
-50,000
Closed -$526K – 1224
2018
Q3 		$526K Buy
+50,000
New +$580K 0.02% 569

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schonfeld Strategic Advisors's SPRO Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Spero Therapeutics (SPRO) in Q1 2026: 20,314 shares worth $47.5K. The stake represents ﹤0.01% of the portfolio and ranks #1972 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in SPRO as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in SPRO in Q3 2018 and has held it in 3 quarters since. The position peaked at $1.48M in Q2 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Schonfeld Strategic Advisors held 20,314 shares of Spero Therapeutics worth $47.5K as of Q1 2026.
  • Spero Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Spero Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1972 holding.
  • Schonfeld Strategic Advisors first reported a position in Spero Therapeutics in Q3 2018 and has held it in 3 quarters since.
  • Schonfeld Strategic Advisors's Spero Therapeutics position peaked at $1.48M in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.